The purpose of this study is to evaluate the effectiveness of two doses of carbetocin (50 mcg vs 100 mcg) in preventing uterine atony during elective cesarean section.
Postpartum hemorrhage is a major cause of mortality and morbidity in the world, and it is most often caused by uterine atony. To prevent this complication, uterotonic medication is used during elective cesarean section. Carbetocin, a long-acting synthetic analogue of oxytocin, has been used for this purpose for many years. This medication has numerous side effects: hypotension, tachycardia, nausea, vomiting, chest pain, etc. Using a smaller dose of carbetocin might lower the incidence of these side effects, without compromising prevention of uterine atony in a low-risk group of patient.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
72
Administration of carbetocin 50 mcg , after clamping the umbilical cord
Administration of carbetocin 100 mcg , after clamping the umbilical cord
Hôpital Saint-François-d'Assise (CHUQ)
Québec, Quebec, Canada
Utilization of a second uterotonic drug
Time frame: First 48 hours of the postpartum
Incidence of side effects
Time frame: During the fifteen minutes following the administration of carbetocin
Incidence of major complications
Time frame: First 48 hours of the postpartum
Drop in hemoglobin measurement
Time frame: on the second post-partum day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.